Quick Answer
Protalix BioTherapeutics, Inc. reported Net Income of -$6.60 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$6.60M | -325.2% |
| 2024 | $2.93M | -64.7% |
| 2023 | $8.31M | +155.7% |
| 2022 | -$14.93M | +45.9% |
| 2021 | -$27.58M | -322.8% |
| 2020 | -$6.52M | +64.3% |
| 2019 | -$18.28M | +30.9% |
| 2018 | -$26.46M | +68.3% |
| 2017 | -$83.44M | -184.1% |
| 2016 | -$29.36M | -150.6% |
| 2015 | $58.04M | +293.8% |
| 2014 | -$29.94M | -7.7% |
| 2013 | -$27.79M | -139.2% |
| 2012 | -$11.62M | +68.2% |
| 2011 | -$36.53M | -26.0% |
| 2010 | -$29.00M | +7.8% |
| 2009 | -$31.44M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.35M | -27.2% | +1336.0% |
| June 30, 2025 | $164.0K | +107.4% | +104.5% |
| March 31, 2025 | -$3.62M | +21.2% | -211.8% |
| September 30, 2024 | $3.24M | +274.7% | +246.9% |
| June 30, 2024 | -$2.20M | -111.4% | +52.1% |
| March 31, 2024 | -$4.59M | -46.8% | -148.1% |
| September 30, 2023 | -$1.85M | +48.1% | -109.6% |
| June 30, 2023 | $19.34M | +462.6% | +717.7% |
- Protalix BioTherapeutics, Inc. showed a decrease of -325.2% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Protalix BioTherapeutics, Inc.’s net income has grown by 79.0% (from -$31.44 million to -$6.60 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: